Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-12-2001 | Paper Report

Activin can activate p38 MAPK

Author: Elena Neumann

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

Activin, a member of the transforming growth factor (TGF)? family of growth factors, is known to be a potential growth inhibitor in various tissues and a potential regulator of inflammation by downregulation of proinflammatory cytokines, like interleukin (IL)-1 and IL-6. Activin is overexpressed in several diseases, e.g. in the synovium of rheumatoid arthritis, which is characterized by inflammation and hyperplasia. Intracellular signaling of cellular growth arrest mediated by activin involves Smad proteins, but other molecular pathways still have to be clarified. The aim of this study was to characterize the intracellular signaling of activin that leads to cell growth inhibition. …
Literature
1.
go back to reference Cocolakis E, Lemay S, Ali S, Lebrun JJ: The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem. 2001, 276: 18430-18436.CrossRefPubMed Cocolakis E, Lemay S, Ali S, Lebrun JJ: The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem. 2001, 276: 18430-18436.CrossRefPubMed
Metadata
Title
Activin can activate p38 MAPK
Author
Elena Neumann
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2001-68468

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine